In situ diselenide-crosslinked polymeric micelles for ROS-mediated anticancer drug delivery

Biomaterials

Volumn 103, Issue , 2016, Pages 56-66

  Deepagan, V G ^a   Kwon, Seunglee ^a   You, Dong Gil ^a   Nguyen, Van Quy ^a   Um, Wooram ^a   Ko, Hyewon ^a   Lee, Hansang ^a   Jo, Dong Gyu ^a   Kang, Young Mo ^b   Park, Jae Hyung ^a  

^a Sungkyunkwan University   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

Biostability; Diselenide bond; Drug delivery; In situ crosslinking; Polymeric micelle; ROS responsive release

Indexed keywords

DRUG DELIVERY; HYDROPHOBICITY; MICELLES; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; POLYMERS; SELENIUM COMPOUNDS; TUMORS;

BIOSTABILITY; DISELENIDE; POLYMERIC MICELLE; ROS-RESPONSIVE RELEASE; SITU CROSS-LINKING;

DRUG THERAPY;

ACETONITRILE; CHLOROFORM; COPOLYMER; DIPHENYL DISELENIDE; DODECYL SULFATE SODIUM; DOXORUBICIN; DRUG CARRIER; MACROGOL; NANOCARRIER; POLYPEPTIDE; PYRUVATE SODIUM; REACTIVE OXYGEN METABOLITE; SELENIUM; WATER; ANTINEOPLASTIC ANTIBIOTIC; CROSS LINKING REAGENT; MACROGOL DERIVATIVE; NANOCAPSULE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS ASSAY; ARTICLE; CHEMICAL BOND; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DIALYSIS MEMBRANE; DISELENIDE BOND; DISELENIDE CROSSLINKED MICELLE; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RELEASE; ENCAPSULATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE OVEREXPRESSION; HYDROPHOBICITY; LIGHT SCATTERING; MICELLE; MICROPLATE READER; MOUSE; MTT ASSAY; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; CHEMISTRY; DRUG STABILITY; EMULSION; EXPERIMENTAL NEOPLASM; HUMAN; MALE; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; PARTICLE SIZE; PROCEDURES; TREATMENT OUTCOME; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CROSS-LINKING REAGENTS; DOXORUBICIN; DRUG STABILITY; EMULSIONS; HUMANS; MALE; MICE; MICE, NUDE; MICELLES; MOLECULAR TARGETED THERAPY; NANOCAPSULES; NEOPLASMS, EXPERIMENTAL; PARTICLE SIZE; POLYETHYLENE GLYCOLS; REACTIVE OXYGEN SPECIES; SELENIUM; TREATMENT OUTCOME;

EID: 84977100976     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.06.044     Document Type: Article

References (39)

1. [1] Davis, M.E., Chen, Z., Shin, D.M., Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7 (2008), 771–782.
2. [2] Mura, S., Couvreur, P., Nanotheranostics for personalized medicine. Adv. Drug Deliv. Rev. 64 (2012), 1394–1416.
3. [3] Ahmad, Z., Shah, A., Siddiq, M., Kraatz, H.B., Polymeric micelles as drug delivery vehicles. RSC Adv. 4 (2014), 17028–17038.
4. [4] Duncan, R., The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2 (2003), 347–360.
5. [5] Han, L.M., Guo, J., Zhang, L.J., Wang, Q.S., Fang, X., Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with Pluronic P123. Acta Pharmacol. Sin. 27 (2006), 747–753.
6. [6] Talelli, M., Barz, M., Rijcken, C.-F., Kiessling, F., Hennink, W.E., Lammers, T., Core-crosslinked polymeric micelles: principles, preparation, biomedical applications and clinical translation. Nano Today 10 (2015), 93–117.
7. [7] Koo, A.N., Lee, H.J., Kim, S.E., Chang, J.H., Park, C., Kim, C., et al. Disulfide-cross-linked PEG-poly(amino acid)s copolymer micelles for glutathione-mediated intracellular drug delivery. Chem. Commun., 2008, 6570–6572.
8. [8] Petros, R.A., DeSimone, J.M., Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 9 (2010), 615–627.
9. [9] Li, Y., Xiao, K., Zhu, W., Deng, W., Lam, K.S., Stimuli-responsive cross-linked micelles for on-demand drug delivery against cancers. Adv. Drug Deliv. Rev. 66 (2014), 58–73.
10. [10] Han, H.S., Thambi, T., Choi, K.Y., Son, S., Ko, H., Lee, M.C., et al. Bioreducible shell-cross-linked hyaluronic acid nanoparticles for tumor-targeted drug delivery. Biomacromolecules 16 (2015), 447–456.
11. [11] Thambi, T., Saravanakumar, G., Chu, J.-U., Heo, R., Ko, H., Deepagan, V.G., et al. Synthesis and physicochemical characterization of reduction-sensitive block copolymer for intracellular delivery of doxorubicin. Macromol. Res. 21 (2013), 100–107.
12. [12] Thambi, T., Deepagan, V.G., Ko, H., Suh, Y.D., Yi, G.-R., Lee, J.Y., et al. Biostable and bioreducible polymersomes for intracellular delivery of doxorubicin. Polym. Chem. 5 (2014), 4627–4634.
13. [13] MacEwan, S.R., Callahan, D.J., Chilkoti, A., Stimulus-responsive macromolecules and nanoparticles for cancer drug delivery. Nanomedicine 5 (2010), 793–806.
14. [14] Saravanakumar, G., Lee, J., Kim, J., Kim, W.J., Visible light-induced singlet oxygen-mediated intracellular disassembly of polymeric micelles co-loaded with a photosensitizer and an anticancer drug for enhanced photodynamic therapy. Chem. Commun. 51 (2015), 9995–9998.
15. [15] Pelicano, H., Carney, D., Huang, P., ROS stress in cancer cells and therapeutic implications. Drug. Resist. Update. 7 (2004), 97–110.
16. [16] Finkel, T., Serrano, M., Blasco, M.A., The common biology of cancer and ageing. Nature 448 (2007), 767–774.
17. [17] López, L.M., Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy. Cancer Lett. 252 (2007), 1–8.
18. [18] Liou, G.Y., Storz, P., Reactive oxygen species in cancer. Free Radic. Res. 44 (2010), 479–496.
19. [19] Bienert, G.P., Schjoerring, J.K., Jahn, T.P., Membrane transport of hydrogen peroxide. Biochim. Biophys. Acta 1758 (2006), 994–1003.
20. [20] D'Autreaux, B., Toledano, M.B., ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat. Rev. Mol. Cell Biol. 8 (2007), 813–824.
21. 2-Sensitive linker. J. Am. Chem. Soc. 133 (2011), 3972–3980.
22. [22] de Gracia Lux, C., Joshi-Barr, S., Nguyen, T., Mahmoud, E., Schopf, E., Fomina, N., et al. Biocompatible polymeric nanoparticles degrade and release cargo in response to biologically relevant levels of hydrogen peroxide. J. Am. Chem. Soc. 134 (2012), 15758–15764.
23. [23] Wilson, D.S., Dalmasso, G., Wang, L., Sitaraman, S.V., Merlin, D., Murthy, N., Orally delivered thioketal nanoparticles loaded with TNF-α–siRNA target inflammation and inhibit gene expression in the intestines. Nat. Mater. 9 (2010), 923–928.
24. [24] Lee, Y.D., Lim, C.K., Singh, A., Koh, J., Kim, J., Kwon, I.C., et al. Dye/Peroxalate aggregated nanoparticles with enhanced and tunable chemiluminescence for biomedical imaging of hydrogen peroxide. ACS Nano 6 (2012), 6759–6766.
25. [25] Xiao, C., Ding, J., Ma, L., Yang, C., Zhuang, X., Chen, X., Synthesis of thermal and oxidation dual responsive polymers for reactive oxygen species (ROS)-triggered drug release. Polym. Chem. 6 (2015), 738–747.
26. [26] Ren, H., Wu, Y., Ma, N., Xu, H., Zhang, X., Side-chain selenium-containing amphiphilic block copolymers: redox-controlled self-assembly and disassembly. Soft Matter 8 (2012), 1460–1466.
27. [27] Cao, W., Gu, Y., Li, T., Xu, H., Ultra-sensitive ROS-responsive tellurium-containing polymers. Chem. Commun. 51 (2015), 7069–7071.
28. [28] Ma, N., Li, Y., Xu, H., Wang, Z., Zhang, X., Dual redox responsive assemblies formed from diselenide block copolymers. J. Am. Chem. Soc. 132 (2010), 442–443.
29. [29] Akagi, D., Oba, M., Koyama, H., Nishiyama, N., Fukushima, S., Miyata, T., et al. Biocompatible micellar nanovectors achieve efficient gene transfer to vascular lesions without cytotoxicity and thrombus formation. Gene. Ther. 14 (2007), 1029–1038.
30. [30] Proline dehydrogenase is essential for proline protection against hydrogen peroxide-induced cell death. Free Radic. Biol. Med. 5 (2012), 1181–1191.
31. [31] Blanco, E., Shen, H., Ferrari, M., Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotech. 33 (2015), 941–951.
32. [32] Tian, Y., Zheng, J., Tang, X., Ren, Q., Wang, Y., Yang, W., Near-infrared light-responsive nanogels with diselenide-cross-linkers for on-demand degradation and triggered drug release. Part. Part. Syst. Char. 32 (2015), 547–551.
33. [33] Wang, F., Wang, Y.C., Dou, S., Xiong, M.H., Sun, T.M., Wang, J., Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in Cancer cells. ACS Nano 5 (2011), 3679–3692.
34. [34] Fan, C., Zheng, W., Fu, X., Li, X., Wong, Y.S., Chen, T., Strategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling. Oncotarget 5 (2014), 2853–2863.
35. [35] Baines, A., Taylor, P.M., Renaud, A.-C., Gerner, E.W., Nelson, M.A., Selenomethionine inhibits growth and suppresses Cyclooxygenase-2 (COX-2) protein expression in human colon Cancer cell lines. Cancer Biol. Ther. 1 (2002), 369–373.
36. [36] Rayman, M.P., Selenium in cancer prevention: a review of the evidence and mechanism of action. P. Nutr. Soc. 64 (2005), 527–542.
37. [37] Michael, M.-S., Michael, T., Shiva, D., Adrienne, G., Wainwright, J., Youcef, R., et al. Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck. World J. Clin. Oncol. 6 (2015), 166–173.
38. [38] Kiaris, H., Schally, A.V., Apoptosis versus necrosis: which should Be the aim of Cancer therapy?. Proc. Soc. Exp. Bio. Med. 221 (1999), 87–88.
39. [39] De, B.-C., Medema, J.P., Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treat. Rev. 34 (2008), 737–749.